

Dawn Maze

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4597204/publications.pdf>

Version: 2024-02-01

37
papers

321
citations

1170033

9
h-index

993246

17
g-index

37
all docs

37
docs citations

37
times ranked

639
citing authors

#	ARTICLE	IF	CITATIONS
1	A t(6;14;9)(p22;q22;q34) translocation: Description of a cytogenetically visible variant t(6;9) in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 983-985.	2.0	3
2	Osteolytic lesion in polycythemia vera: First report and review of literature. <i>EJHaem</i> , 2022, 3, 526-532.	0.4	0
3	Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort. <i>Leukemia</i> , 2022, 36, 1689-1692.	3.3	4
4	Risk of hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients with myeloproliferative neoplasms treated with ruxolitinib. <i>Leukemia and Lymphoma</i> , 2021, 62, 495-497.	0.6	4
5	Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series. <i>Leukemia and Lymphoma</i> , 2021, 62, 1525-1527.	0.6	2
6	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 1908-1918.	1.3	10
7	Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study. <i>British Journal of Haematology</i> , 2021, 194, 557-567.	1.2	6
8	Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 600.e1-600.e8.	0.6	5
9	Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen. <i>Current Oncology</i> , 2021, 28, 128-137.	0.9	1
10	Risk factors for intracranial hemorrhage in adults with acute leukemia. <i>Transfusion</i> , 2021, 61, 3303-3308.	0.8	4
11	Clinical outcomes and transfusion management following intracranial hemorrhage in patients with acute leukemia. <i>Transfusion</i> , 2020, 60, 269-274.	0.8	5
12	Combination treatment with CPX351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature. <i>British Journal of Haematology</i> , 2020, 190, 467-470.	1.2	2
13	Total body irradiation (18% Gy) without chemotherapy as conditioning for allogeneic hematopoietic cell transplantation in refractory acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 1454-1456.	1.3	2
14	Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS. <i>Blood</i> , 2020, 136, 1-2.	0.6	2
15	Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA. <i>Blood</i> , 2020, 136, 35-36.	0.6	0
16	Geographical Distance from Quaternary Treatment Center Does Not Impact Choice of Upfront Therapy, Clinical Trial Participation and Outcomes in Patients with Newly Diagnosed AML. <i>Blood</i> , 2020, 136, 15-16.	0.6	0
17	Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Harboring DNMT3A/TET2/ASXL1 Mutation. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
18	CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study. <i>Blood</i> , 2020, 136, 6-7.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era. <i>Blood</i> , 2020, 136, 52-53.	0.6	1
20	Clinical Significance of Emergent Leukocytosis in Patients with Myelofibrosis Receiving JAK Inhibitor Therapy. <i>Blood</i> , 2020, 136, 22-22.	0.6	0
21	A case of secondary acute myeloid leukemia on a background of glycogen storage disease with chronic neutropenia treated with granulocyte colony stimulating factor. <i>JIMD Reports</i> , 2019, 49, 37-42.	0.7	6
22	Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML. <i>Blood Advances</i> , 2019, 3, 2307-2311.	2.5	12
23	Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. <i>Current Opinion in Hematology</i> , 2019, 26, 16-21.	1.2	46
24	Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family. <i>Blood</i> , 2019, 134, 3498-3498.	0.6	2
25	HSCs Fated to Progress to Blast Phase Can be Detected in Myelofibrosis Patients Several Years Prior to Leukemic Transformation. <i>Blood</i> , 2019, 134, 1676-1676.	0.6	0
26	Clinical Interventions to Prevent Tumour Lysis Syndrome in Hematologic Malignancy: A Multisite Retrospective Chart Review. <i>Canadian Journal of Hospital Pharmacy</i> , 2019, 72, 435-445.	0.1	2
27	Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length. <i>Pediatric Hematology and Oncology</i> , 2018, 35, 45-51.	0.3	31
28	Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers. <i>Blood Cancer Journal</i> , 2018, 8, 14.	2.8	3
29	The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. <i>Blood Advances</i> , 2018, 2, 2658-2671.	2.5	47
30	Clinical Utility of Next-Generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience. <i>HemaSphere</i> , 2018, 2, e44.	1.2	19
31	Delayed Hematologic Recovery in AML Patients after Induction Chemotherapy Is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations. <i>Blood</i> , 2018, 132, 992-992.	0.6	0
32	Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2096-2101.	2.0	27
33	Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 774-781.	0.2	6
34	Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. <i>Blood Advances</i> , 2017, 1, 1729-1738.	2.5	48
35	Total Body Irradiation without Chemotherapy as Conditioning for an Allogeneic Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2016, 2016, 1-7.	0.3	2
36	Optimal transfusion practices after allogeneic hematopoietic cell transplantation: a systematic scoping review of evidence from randomized controlled trials. <i>Transfusion</i> , 2016, 56, 2607-2614.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study. <i>BMJ Open</i> , 2016, 6, e013483.	0.8	6